nodes	percent_of_prediction	percent_of_DWPC	metapath
Loxapine—HTR2A—phrenic nerve—lung cancer	0.02	0.187	CbGeAlD
Loxapine—HTR7—pulmonary artery—lung cancer	0.0117	0.109	CbGeAlD
Loxapine—HTR2A—pulmonary artery—lung cancer	0.00727	0.068	CbGeAlD
Loxapine—HRH4—bone marrow—lung cancer	0.00539	0.0504	CbGeAlD
Loxapine—CHRM5—epithelium—lung cancer	0.00308	0.0288	CbGeAlD
Loxapine—HTR3A—respiratory system—lung cancer	0.00303	0.0284	CbGeAlD
Loxapine—HRH2—cardiac atrium—lung cancer	0.00268	0.0251	CbGeAlD
Loxapine—SLC6A3—respiratory system—lung cancer	0.00252	0.0236	CbGeAlD
Loxapine—SLC6A4—respiratory system—lung cancer	0.00231	0.0216	CbGeAlD
Loxapine—HRH2—lung—lung cancer	0.00205	0.0192	CbGeAlD
Loxapine—SLC6A2—respiratory system—lung cancer	0.00204	0.019	CbGeAlD
Loxapine—ADRB1—bronchus—lung cancer	0.00197	0.0184	CbGeAlD
Loxapine—HTR7—respiratory system—lung cancer	0.00196	0.0184	CbGeAlD
Loxapine—DRD2—respiratory system—lung cancer	0.00185	0.0174	CbGeAlD
Loxapine—CHRM1—trachea—lung cancer	0.0017	0.0159	CbGeAlD
Loxapine—ADRB1—cardiac atrium—lung cancer	0.00166	0.0155	CbGeAlD
Loxapine—HTR7—epithelium—lung cancer	0.00164	0.0153	CbGeAlD
Loxapine—HTR3A—lung—lung cancer	0.00161	0.0151	CbGeAlD
Loxapine—ADRA1A—epithelium—lung cancer	0.00158	0.0148	CbGeAlD
Loxapine—ADRA2C—bronchus—lung cancer	0.00148	0.0139	CbGeAlD
Loxapine—HRH1—respiratory system—lung cancer	0.00146	0.0137	CbGeAlD
Loxapine—HTR7—trachea—lung cancer	0.00145	0.0136	CbGeAlD
Loxapine—HRH2—lymph node—lung cancer	0.0014	0.0131	CbGeAlD
Loxapine—SLC6A3—lung—lung cancer	0.00134	0.0125	CbGeAlD
Loxapine—ADRA2C—trachea—lung cancer	0.00133	0.0125	CbGeAlD
Loxapine—ADRB1—lung—lung cancer	0.00127	0.0119	CbGeAlD
Loxapine—ADRA2C—cardiac atrium—lung cancer	0.00125	0.0117	CbGeAlD
Loxapine—SLC6A4—lung—lung cancer	0.00123	0.0115	CbGeAlD
Loxapine—HRH1—epithelium—lung cancer	0.00122	0.0115	CbGeAlD
Loxapine—HTR2A—respiratory system—lung cancer	0.00122	0.0114	CbGeAlD
Loxapine—CHRM1—lung—lung cancer	0.00122	0.0114	CbGeAlD
Loxapine—ADRA2A—bronchus—lung cancer	0.00118	0.0111	CbGeAlD
Loxapine—Azelastine—CYP2A6—lung cancer	0.00113	0.15	CrCbGaD
Loxapine—HRH1—trachea—lung cancer	0.00108	0.0101	CbGeAlD
Loxapine—SLC6A2—lung—lung cancer	0.00108	0.0101	CbGeAlD
Loxapine—ADRA2A—trachea—lung cancer	0.00106	0.00995	CbGeAlD
Loxapine—HTR7—lung—lung cancer	0.00104	0.00974	CbGeAlD
Loxapine—HTR2A—epithelium—lung cancer	0.00102	0.00956	CbGeAlD
Loxapine—ADRA2A—cardiac atrium—lung cancer	0.000999	0.00934	CbGeAlD
Loxapine—DRD2—lung—lung cancer	0.000985	0.00921	CbGeAlD
Loxapine—ADRA2C—lung—lung cancer	0.000957	0.00896	CbGeAlD
Loxapine—HTR2A—trachea—lung cancer	0.000904	0.00846	CbGeAlD
Loxapine—Azelastine—CYP2E1—lung cancer	0.000802	0.107	CrCbGaD
Loxapine—Azelastine—CYP1A1—lung cancer	0.000791	0.105	CrCbGaD
Loxapine—HRH1—lung—lung cancer	0.000778	0.00728	CbGeAlD
Loxapine—ADRA2A—lung—lung cancer	0.000764	0.00715	CbGeAlD
Loxapine—SLC6A2—lymph node—lung cancer	0.000739	0.00691	CbGeAlD
Loxapine—ADRA2C—lymph node—lung cancer	0.000655	0.00613	CbGeAlD
Loxapine—HTR2A—lung—lung cancer	0.00065	0.00608	CbGeAlD
Loxapine—Agitation—Paclitaxel—lung cancer	0.000589	0.00119	CcSEcCtD
Loxapine—Headache—Vinblastine—lung cancer	0.000586	0.00118	CcSEcCtD
Loxapine—Leukopenia—Etoposide—lung cancer	0.000585	0.00118	CcSEcCtD
Loxapine—Hypotension—Gemcitabine—lung cancer	0.000584	0.00118	CcSEcCtD
Loxapine—Oedema—Cisplatin—lung cancer	0.000582	0.00117	CcSEcCtD
Loxapine—Insomnia—Irinotecan—lung cancer	0.00058	0.00117	CcSEcCtD
Loxapine—Vomiting—Topotecan—lung cancer	0.000578	0.00117	CcSEcCtD
Loxapine—Paraesthesia—Irinotecan—lung cancer	0.000576	0.00116	CcSEcCtD
Loxapine—Syncope—Paclitaxel—lung cancer	0.000575	0.00116	CcSEcCtD
Loxapine—Loss of consciousness—Etoposide—lung cancer	0.000575	0.00116	CcSEcCtD
Loxapine—Cerebrovascular accident—Doxorubicin—lung cancer	0.000575	0.00116	CcSEcCtD
Loxapine—Leukopenia—Paclitaxel—lung cancer	0.000574	0.00116	CcSEcCtD
Loxapine—Rash—Topotecan—lung cancer	0.000573	0.00116	CcSEcCtD
Loxapine—Hypersensitivity—Vinorelbine—lung cancer	0.000573	0.00116	CcSEcCtD
Loxapine—Dermatitis—Topotecan—lung cancer	0.000573	0.00116	CcSEcCtD
Loxapine—Vomiting—Erlotinib—lung cancer	0.000572	0.00115	CcSEcCtD
Loxapine—Dyspnoea—Irinotecan—lung cancer	0.000572	0.00115	CcSEcCtD
Loxapine—Nervous system disorder—Cisplatin—lung cancer	0.000571	0.00115	CcSEcCtD
Loxapine—Cough—Etoposide—lung cancer	0.00057	0.00115	CcSEcCtD
Loxapine—Somnolence—Irinotecan—lung cancer	0.00057	0.00115	CcSEcCtD
Loxapine—Thrombocytopenia—Cisplatin—lung cancer	0.00057	0.00115	CcSEcCtD
Loxapine—Headache—Topotecan—lung cancer	0.00057	0.00115	CcSEcCtD
Loxapine—Tachycardia—Cisplatin—lung cancer	0.000568	0.00115	CcSEcCtD
Loxapine—Rash—Erlotinib—lung cancer	0.000567	0.00114	CcSEcCtD
Loxapine—Dermatitis—Erlotinib—lung cancer	0.000567	0.00114	CcSEcCtD
Loxapine—Convulsion—Etoposide—lung cancer	0.000566	0.00114	CcSEcCtD
Loxapine—Angiopathy—Docetaxel—lung cancer	0.000566	0.00114	CcSEcCtD
Loxapine—Insomnia—Gemcitabine—lung cancer	0.000565	0.00114	CcSEcCtD
Loxapine—Hypertension—Etoposide—lung cancer	0.000564	0.00114	CcSEcCtD
Loxapine—Headache—Erlotinib—lung cancer	0.000563	0.00114	CcSEcCtD
Loxapine—Loss of consciousness—Paclitaxel—lung cancer	0.000563	0.00114	CcSEcCtD
Loxapine—Mediastinal disorder—Docetaxel—lung cancer	0.000562	0.00113	CcSEcCtD
Loxapine—Paraesthesia—Gemcitabine—lung cancer	0.000561	0.00113	CcSEcCtD
Loxapine—Cough—Paclitaxel—lung cancer	0.000559	0.00113	CcSEcCtD
Loxapine—Asthenia—Vinorelbine—lung cancer	0.000558	0.00113	CcSEcCtD
Loxapine—Dyspnoea—Gemcitabine—lung cancer	0.000557	0.00112	CcSEcCtD
Loxapine—Chest pain—Etoposide—lung cancer	0.000557	0.00112	CcSEcCtD
Loxapine—Nausea—Vinblastine—lung cancer	0.000556	0.00112	CcSEcCtD
Loxapine—Somnolence—Gemcitabine—lung cancer	0.000555	0.00112	CcSEcCtD
Loxapine—Convulsion—Paclitaxel—lung cancer	0.000555	0.00112	CcSEcCtD
Loxapine—Gastrointestinal disorder—Irinotecan—lung cancer	0.000554	0.00112	CcSEcCtD
Loxapine—Hypertension—Paclitaxel—lung cancer	0.000553	0.00112	CcSEcCtD
Loxapine—Fatigue—Irinotecan—lung cancer	0.000553	0.00112	CcSEcCtD
Loxapine—Alopecia—Docetaxel—lung cancer	0.000551	0.00111	CcSEcCtD
Loxapine—Pruritus—Vinorelbine—lung cancer	0.00055	0.00111	CcSEcCtD
Loxapine—Constipation—Irinotecan—lung cancer	0.000548	0.00111	CcSEcCtD
Loxapine—Chest pain—Paclitaxel—lung cancer	0.000546	0.0011	CcSEcCtD
Loxapine—Hypotension—Cisplatin—lung cancer	0.000544	0.0011	CcSEcCtD
Loxapine—Nausea—Topotecan—lung cancer	0.00054	0.00109	CcSEcCtD
Loxapine—Gastrointestinal disorder—Gemcitabine—lung cancer	0.000539	0.00109	CcSEcCtD
Loxapine—Fatigue—Gemcitabine—lung cancer	0.000539	0.00109	CcSEcCtD
Loxapine—Confusional state—Etoposide—lung cancer	0.000538	0.00108	CcSEcCtD
Loxapine—Constipation—Gemcitabine—lung cancer	0.000534	0.00108	CcSEcCtD
Loxapine—Nausea—Erlotinib—lung cancer	0.000534	0.00108	CcSEcCtD
Loxapine—Dry mouth—Paclitaxel—lung cancer	0.000534	0.00108	CcSEcCtD
Loxapine—Dysgeusia—Docetaxel—lung cancer	0.000532	0.00107	CcSEcCtD
Loxapine—HRH1—lymph node—lung cancer	0.000532	0.00498	CbGeAlD
Loxapine—Feeling abnormal—Irinotecan—lung cancer	0.000529	0.00107	CcSEcCtD
Loxapine—Confusional state—Paclitaxel—lung cancer	0.000527	0.00106	CcSEcCtD
Loxapine—Oedema—Paclitaxel—lung cancer	0.000523	0.00106	CcSEcCtD
Loxapine—Paraesthesia—Cisplatin—lung cancer	0.000523	0.00105	CcSEcCtD
Loxapine—ADRA2A—lymph node—lung cancer	0.000523	0.00489	CbGeAlD
Loxapine—Thrombocytopenia—Etoposide—lung cancer	0.000522	0.00105	CcSEcCtD
Loxapine—Muscle spasms—Docetaxel—lung cancer	0.000522	0.00105	CcSEcCtD
Loxapine—Tachycardia—Etoposide—lung cancer	0.000521	0.00105	CcSEcCtD
Loxapine—Dyspnoea—Cisplatin—lung cancer	0.000519	0.00105	CcSEcCtD
Loxapine—Feeling abnormal—Gemcitabine—lung cancer	0.000515	0.00104	CcSEcCtD
Loxapine—Shock—Paclitaxel—lung cancer	0.000515	0.00104	CcSEcCtD
Loxapine—Dizziness—Vinorelbine—lung cancer	0.000514	0.00104	CcSEcCtD
Loxapine—Orthostatic hypotension—Doxorubicin—lung cancer	0.000514	0.00104	CcSEcCtD
Loxapine—Nervous system disorder—Paclitaxel—lung cancer	0.000513	0.00103	CcSEcCtD
Loxapine—Photosensitivity reaction—Methotrexate—lung cancer	0.000513	0.00103	CcSEcCtD
Loxapine—Thrombocytopenia—Paclitaxel—lung cancer	0.000512	0.00103	CcSEcCtD
Loxapine—Tachycardia—Paclitaxel—lung cancer	0.000511	0.00103	CcSEcCtD
Loxapine—Clozapine—CYP2A6—lung cancer	0.000506	0.0674	CrCbGaD
Loxapine—Gastrointestinal disorder—Cisplatin—lung cancer	0.000503	0.00101	CcSEcCtD
Loxapine—Drowsiness—Methotrexate—lung cancer	0.000501	0.00101	CcSEcCtD
Loxapine—Hypotension—Etoposide—lung cancer	0.000499	0.00101	CcSEcCtD
Loxapine—Vomiting—Vinorelbine—lung cancer	0.000494	0.000997	CcSEcCtD
Loxapine—Renal failure—Methotrexate—lung cancer	0.000493	0.000993	CcSEcCtD
Loxapine—Rash—Vinorelbine—lung cancer	0.00049	0.000989	CcSEcCtD
Loxapine—Dermatitis—Vinorelbine—lung cancer	0.00049	0.000988	CcSEcCtD
Loxapine—Hypotension—Paclitaxel—lung cancer	0.000489	0.000986	CcSEcCtD
Loxapine—Headache—Vinorelbine—lung cancer	0.000487	0.000983	CcSEcCtD
Loxapine—Syncope—Docetaxel—lung cancer	0.000487	0.000983	CcSEcCtD
Loxapine—Dysphagia—Doxorubicin—lung cancer	0.000487	0.000981	CcSEcCtD
Loxapine—Leukopenia—Docetaxel—lung cancer	0.000486	0.000981	CcSEcCtD
Loxapine—Feeling abnormal—Cisplatin—lung cancer	0.00048	0.000968	CcSEcCtD
Loxapine—Paraesthesia—Etoposide—lung cancer	0.000479	0.000966	CcSEcCtD
Loxapine—Loss of consciousness—Docetaxel—lung cancer	0.000477	0.000963	CcSEcCtD
Loxapine—Dyspnoea—Etoposide—lung cancer	0.000476	0.000959	CcSEcCtD
Loxapine—Somnolence—Etoposide—lung cancer	0.000474	0.000957	CcSEcCtD
Loxapine—Cough—Docetaxel—lung cancer	0.000474	0.000956	CcSEcCtD
Loxapine—Insomnia—Paclitaxel—lung cancer	0.000473	0.000954	CcSEcCtD
Loxapine—Hypersensitivity—Irinotecan—lung cancer	0.000473	0.000953	CcSEcCtD
Loxapine—Convulsion—Docetaxel—lung cancer	0.000471	0.000949	CcSEcCtD
Loxapine—Paraesthesia—Paclitaxel—lung cancer	0.00047	0.000947	CcSEcCtD
Loxapine—Hypertension—Docetaxel—lung cancer	0.000469	0.000946	CcSEcCtD
Loxapine—Agranulocytosis—Methotrexate—lung cancer	0.000468	0.000943	CcSEcCtD
Loxapine—Dyspnoea—Paclitaxel—lung cancer	0.000466	0.000941	CcSEcCtD
Loxapine—Somnolence—Paclitaxel—lung cancer	0.000465	0.000938	CcSEcCtD
Loxapine—Chest pain—Docetaxel—lung cancer	0.000463	0.000933	CcSEcCtD
Loxapine—Nausea—Vinorelbine—lung cancer	0.000462	0.000932	CcSEcCtD
Loxapine—Gastrointestinal disorder—Etoposide—lung cancer	0.000461	0.000929	CcSEcCtD
Loxapine—Asthenia—Irinotecan—lung cancer	0.00046	0.000928	CcSEcCtD
Loxapine—Fatigue—Etoposide—lung cancer	0.00046	0.000928	CcSEcCtD
Loxapine—Constipation—Etoposide—lung cancer	0.000456	0.00092	CcSEcCtD
Loxapine—Dry mouth—Docetaxel—lung cancer	0.000452	0.000912	CcSEcCtD
Loxapine—Gastrointestinal disorder—Paclitaxel—lung cancer	0.000452	0.000911	CcSEcCtD
Loxapine—Fatigue—Paclitaxel—lung cancer	0.000451	0.00091	CcSEcCtD
Loxapine—Hepatitis—Methotrexate—lung cancer	0.00045	0.000907	CcSEcCtD
Loxapine—Asthenia—Gemcitabine—lung cancer	0.000448	0.000904	CcSEcCtD
Loxapine—Constipation—Paclitaxel—lung cancer	0.000447	0.000902	CcSEcCtD
Loxapine—Confusional state—Docetaxel—lung cancer	0.000447	0.000902	CcSEcCtD
Loxapine—Photosensitivity reaction—Doxorubicin—lung cancer	0.000444	0.000896	CcSEcCtD
Loxapine—Oedema—Docetaxel—lung cancer	0.000443	0.000894	CcSEcCtD
Loxapine—Weight increased—Doxorubicin—lung cancer	0.000443	0.000893	CcSEcCtD
Loxapine—Pruritus—Gemcitabine—lung cancer	0.000442	0.000892	CcSEcCtD
Loxapine—Weight decreased—Doxorubicin—lung cancer	0.00044	0.000888	CcSEcCtD
Loxapine—Feeling abnormal—Etoposide—lung cancer	0.00044	0.000887	CcSEcCtD
Loxapine—Shock—Docetaxel—lung cancer	0.000436	0.00088	CcSEcCtD
Loxapine—Nervous system disorder—Docetaxel—lung cancer	0.000435	0.000877	CcSEcCtD
Loxapine—Thrombocytopenia—Docetaxel—lung cancer	0.000434	0.000876	CcSEcCtD
Loxapine—Drowsiness—Doxorubicin—lung cancer	0.000434	0.000875	CcSEcCtD
Loxapine—Tachycardia—Docetaxel—lung cancer	0.000433	0.000873	CcSEcCtD
Loxapine—Feeling abnormal—Paclitaxel—lung cancer	0.000431	0.000869	CcSEcCtD
Loxapine—Hypersensitivity—Cisplatin—lung cancer	0.000429	0.000865	CcSEcCtD
Loxapine—Renal failure—Doxorubicin—lung cancer	0.000426	0.00086	CcSEcCtD
Loxapine—Dizziness—Irinotecan—lung cancer	0.000424	0.000855	CcSEcCtD
Loxapine—Jaundice—Doxorubicin—lung cancer	0.000423	0.000853	CcSEcCtD
Loxapine—Azelastine—ABCB1—lung cancer	0.00042	0.056	CrCbGaD
Loxapine—Asthenia—Cisplatin—lung cancer	0.000418	0.000843	CcSEcCtD
Loxapine—Hypotension—Docetaxel—lung cancer	0.000414	0.000836	CcSEcCtD
Loxapine—Angiopathy—Methotrexate—lung cancer	0.000408	0.000823	CcSEcCtD
Loxapine—Vomiting—Irinotecan—lung cancer	0.000408	0.000823	CcSEcCtD
Loxapine—Mediastinal disorder—Methotrexate—lung cancer	0.000405	0.000818	CcSEcCtD
Loxapine—Agranulocytosis—Doxorubicin—lung cancer	0.000405	0.000817	CcSEcCtD
Loxapine—Rash—Irinotecan—lung cancer	0.000404	0.000816	CcSEcCtD
Loxapine—Dermatitis—Irinotecan—lung cancer	0.000404	0.000815	CcSEcCtD
Loxapine—Headache—Irinotecan—lung cancer	0.000402	0.00081	CcSEcCtD
Loxapine—Insomnia—Docetaxel—lung cancer	0.000401	0.000809	CcSEcCtD
Loxapine—Paraesthesia—Docetaxel—lung cancer	0.000398	0.000803	CcSEcCtD
Loxapine—Alopecia—Methotrexate—lung cancer	0.000397	0.000802	CcSEcCtD
Loxapine—Vomiting—Gemcitabine—lung cancer	0.000397	0.000801	CcSEcCtD
Loxapine—Dyspnoea—Docetaxel—lung cancer	0.000395	0.000797	CcSEcCtD
Loxapine—Somnolence—Docetaxel—lung cancer	0.000394	0.000795	CcSEcCtD
Loxapine—Rash—Gemcitabine—lung cancer	0.000394	0.000795	CcSEcCtD
Loxapine—Dermatitis—Gemcitabine—lung cancer	0.000394	0.000794	CcSEcCtD
Loxapine—Hypersensitivity—Etoposide—lung cancer	0.000393	0.000793	CcSEcCtD
Loxapine—Headache—Gemcitabine—lung cancer	0.000391	0.000789	CcSEcCtD
Loxapine—Hepatitis—Doxorubicin—lung cancer	0.000389	0.000786	CcSEcCtD
Loxapine—Hypoaesthesia—Doxorubicin—lung cancer	0.000388	0.000782	CcSEcCtD
Loxapine—Hypersensitivity—Paclitaxel—lung cancer	0.000385	0.000777	CcSEcCtD
Loxapine—Dysgeusia—Methotrexate—lung cancer	0.000383	0.000773	CcSEcCtD
Loxapine—Gastrointestinal disorder—Docetaxel—lung cancer	0.000383	0.000772	CcSEcCtD
Loxapine—Asthenia—Etoposide—lung cancer	0.000383	0.000772	CcSEcCtD
Loxapine—Fatigue—Docetaxel—lung cancer	0.000382	0.000771	CcSEcCtD
Loxapine—Nausea—Irinotecan—lung cancer	0.000381	0.000768	CcSEcCtD
Loxapine—Constipation—Docetaxel—lung cancer	0.000379	0.000765	CcSEcCtD
Loxapine—Olanzapine—ALB—lung cancer	0.000378	0.0504	CrCbGaD
Loxapine—Pruritus—Etoposide—lung cancer	0.000377	0.000761	CcSEcCtD
Loxapine—Asthenia—Paclitaxel—lung cancer	0.000375	0.000757	CcSEcCtD
Loxapine—Nausea—Gemcitabine—lung cancer	0.000371	0.000749	CcSEcCtD
Loxapine—Vomiting—Cisplatin—lung cancer	0.00037	0.000747	CcSEcCtD
Loxapine—Pruritus—Paclitaxel—lung cancer	0.00037	0.000746	CcSEcCtD
Loxapine—Vision blurred—Methotrexate—lung cancer	0.000369	0.000744	CcSEcCtD
Loxapine—Rash—Cisplatin—lung cancer	0.000367	0.000741	CcSEcCtD
Loxapine—Dermatitis—Cisplatin—lung cancer	0.000367	0.00074	CcSEcCtD
Loxapine—Feeling abnormal—Docetaxel—lung cancer	0.000365	0.000737	CcSEcCtD
Loxapine—Diazepam—CYP2E1—lung cancer	0.000364	0.0485	CrCbGaD
Loxapine—Olanzapine—ABCB1—lung cancer	0.000361	0.0481	CrCbGaD
Loxapine—Clozapine—CYP2E1—lung cancer	0.000359	0.0479	CrCbGaD
Loxapine—Clozapine—CYP1A1—lung cancer	0.000355	0.0472	CrCbGaD
Loxapine—Angiopathy—Doxorubicin—lung cancer	0.000353	0.000713	CcSEcCtD
Loxapine—Dizziness—Etoposide—lung cancer	0.000353	0.000712	CcSEcCtD
Loxapine—Mediastinal disorder—Doxorubicin—lung cancer	0.000351	0.000708	CcSEcCtD
Loxapine—Leukopenia—Methotrexate—lung cancer	0.00035	0.000707	CcSEcCtD
Loxapine—Trazodone—ABCB1—lung cancer	0.000349	0.0465	CrCbGaD
Loxapine—Dizziness—Paclitaxel—lung cancer	0.000346	0.000698	CcSEcCtD
Loxapine—Nausea—Cisplatin—lung cancer	0.000346	0.000698	CcSEcCtD
Loxapine—Alopecia—Doxorubicin—lung cancer	0.000344	0.000694	CcSEcCtD
Loxapine—Thiothixene—ALB—lung cancer	0.000343	0.0456	CrCbGaD
Loxapine—Cough—Methotrexate—lung cancer	0.000342	0.000689	CcSEcCtD
Loxapine—Convulsion—Methotrexate—lung cancer	0.000339	0.000684	CcSEcCtD
Loxapine—Vomiting—Etoposide—lung cancer	0.000339	0.000684	CcSEcCtD
Loxapine—Rash—Etoposide—lung cancer	0.000336	0.000678	CcSEcCtD
Loxapine—Dermatitis—Etoposide—lung cancer	0.000336	0.000678	CcSEcCtD
Loxapine—Headache—Etoposide—lung cancer	0.000334	0.000674	CcSEcCtD
Loxapine—Chest pain—Methotrexate—lung cancer	0.000333	0.000672	CcSEcCtD
Loxapine—Tension—Doxorubicin—lung cancer	0.000333	0.000671	CcSEcCtD
Loxapine—Vomiting—Paclitaxel—lung cancer	0.000333	0.000671	CcSEcCtD
Loxapine—Dysgeusia—Doxorubicin—lung cancer	0.000332	0.00067	CcSEcCtD
Loxapine—Rash—Paclitaxel—lung cancer	0.00033	0.000665	CcSEcCtD
Loxapine—Dermatitis—Paclitaxel—lung cancer	0.00033	0.000665	CcSEcCtD
Loxapine—Headache—Paclitaxel—lung cancer	0.000328	0.000661	CcSEcCtD
Loxapine—Clobazam—ABCB1—lung cancer	0.000327	0.0435	CrCbGaD
Loxapine—Hypersensitivity—Docetaxel—lung cancer	0.000327	0.000659	CcSEcCtD
Loxapine—Muscle spasms—Doxorubicin—lung cancer	0.000326	0.000657	CcSEcCtD
Loxapine—Confusional state—Methotrexate—lung cancer	0.000322	0.00065	CcSEcCtD
Loxapine—Vision blurred—Doxorubicin—lung cancer	0.00032	0.000644	CcSEcCtD
Loxapine—Asthenia—Docetaxel—lung cancer	0.000318	0.000642	CcSEcCtD
Loxapine—Nausea—Etoposide—lung cancer	0.000317	0.000639	CcSEcCtD
Loxapine—Pruritus—Docetaxel—lung cancer	0.000314	0.000633	CcSEcCtD
Loxapine—Nervous system disorder—Methotrexate—lung cancer	0.000313	0.000632	CcSEcCtD
Loxapine—Thrombocytopenia—Methotrexate—lung cancer	0.000313	0.000631	CcSEcCtD
Loxapine—Agitation—Doxorubicin—lung cancer	0.000312	0.000628	CcSEcCtD
Loxapine—Nausea—Paclitaxel—lung cancer	0.000311	0.000627	CcSEcCtD
Loxapine—Syncope—Doxorubicin—lung cancer	0.000304	0.000613	CcSEcCtD
Loxapine—Leukopenia—Doxorubicin—lung cancer	0.000303	0.000612	CcSEcCtD
Loxapine—Hypotension—Methotrexate—lung cancer	0.000299	0.000602	CcSEcCtD
Loxapine—Loss of consciousness—Doxorubicin—lung cancer	0.000298	0.000601	CcSEcCtD
Loxapine—Cough—Doxorubicin—lung cancer	0.000296	0.000597	CcSEcCtD
Loxapine—Convulsion—Doxorubicin—lung cancer	0.000294	0.000592	CcSEcCtD
Loxapine—Dizziness—Docetaxel—lung cancer	0.000293	0.000591	CcSEcCtD
Loxapine—Hypertension—Doxorubicin—lung cancer	0.000293	0.00059	CcSEcCtD
Loxapine—Insomnia—Methotrexate—lung cancer	0.000289	0.000583	CcSEcCtD
Loxapine—Chest pain—Doxorubicin—lung cancer	0.000289	0.000582	CcSEcCtD
Loxapine—Paraesthesia—Methotrexate—lung cancer	0.000287	0.000579	CcSEcCtD
Loxapine—Dyspnoea—Methotrexate—lung cancer	0.000285	0.000575	CcSEcCtD
Loxapine—Somnolence—Methotrexate—lung cancer	0.000284	0.000573	CcSEcCtD
Loxapine—Dry mouth—Doxorubicin—lung cancer	0.000282	0.000569	CcSEcCtD
Loxapine—Vomiting—Docetaxel—lung cancer	0.000282	0.000569	CcSEcCtD
Loxapine—Rash—Docetaxel—lung cancer	0.00028	0.000564	CcSEcCtD
Loxapine—Dermatitis—Docetaxel—lung cancer	0.000279	0.000563	CcSEcCtD
Loxapine—Confusional state—Doxorubicin—lung cancer	0.000279	0.000563	CcSEcCtD
Loxapine—Headache—Docetaxel—lung cancer	0.000278	0.00056	CcSEcCtD
Loxapine—Oedema—Doxorubicin—lung cancer	0.000277	0.000558	CcSEcCtD
Loxapine—Gastrointestinal disorder—Methotrexate—lung cancer	0.000276	0.000556	CcSEcCtD
Loxapine—Fatigue—Methotrexate—lung cancer	0.000276	0.000556	CcSEcCtD
Loxapine—Shock—Doxorubicin—lung cancer	0.000272	0.000549	CcSEcCtD
Loxapine—Nervous system disorder—Doxorubicin—lung cancer	0.000271	0.000547	CcSEcCtD
Loxapine—Thrombocytopenia—Doxorubicin—lung cancer	0.000271	0.000546	CcSEcCtD
Loxapine—Tachycardia—Doxorubicin—lung cancer	0.00027	0.000545	CcSEcCtD
Loxapine—Nausea—Docetaxel—lung cancer	0.000263	0.000531	CcSEcCtD
Loxapine—Feeling abnormal—Methotrexate—lung cancer	0.000263	0.000531	CcSEcCtD
Loxapine—Hypotension—Doxorubicin—lung cancer	0.000259	0.000522	CcSEcCtD
Loxapine—Insomnia—Doxorubicin—lung cancer	0.00025	0.000505	CcSEcCtD
Loxapine—Paraesthesia—Doxorubicin—lung cancer	0.000248	0.000501	CcSEcCtD
Loxapine—Dyspnoea—Doxorubicin—lung cancer	0.000247	0.000498	CcSEcCtD
Loxapine—Somnolence—Doxorubicin—lung cancer	0.000246	0.000496	CcSEcCtD
Loxapine—Gastrointestinal disorder—Doxorubicin—lung cancer	0.000239	0.000482	CcSEcCtD
Loxapine—Fatigue—Doxorubicin—lung cancer	0.000239	0.000481	CcSEcCtD
Loxapine—Constipation—Doxorubicin—lung cancer	0.000237	0.000477	CcSEcCtD
Loxapine—Hypersensitivity—Methotrexate—lung cancer	0.000235	0.000475	CcSEcCtD
Loxapine—Asthenia—Methotrexate—lung cancer	0.000229	0.000462	CcSEcCtD
Loxapine—Feeling abnormal—Doxorubicin—lung cancer	0.000228	0.00046	CcSEcCtD
Loxapine—Pruritus—Methotrexate—lung cancer	0.000226	0.000456	CcSEcCtD
Loxapine—Trifluoperazine—ABCB1—lung cancer	0.000226	0.0301	CrCbGaD
Loxapine—Quetiapine—ABCB1—lung cancer	0.000219	0.0292	CrCbGaD
Loxapine—Dizziness—Methotrexate—lung cancer	0.000211	0.000426	CcSEcCtD
Loxapine—Hypersensitivity—Doxorubicin—lung cancer	0.000204	0.000411	CcSEcCtD
Loxapine—Vomiting—Methotrexate—lung cancer	0.000203	0.00041	CcSEcCtD
Loxapine—Rash—Methotrexate—lung cancer	0.000201	0.000406	CcSEcCtD
Loxapine—Dermatitis—Methotrexate—lung cancer	0.000201	0.000406	CcSEcCtD
Loxapine—Headache—Methotrexate—lung cancer	0.0002	0.000404	CcSEcCtD
Loxapine—Diazepam—ALB—lung cancer	0.0002	0.0266	CrCbGaD
Loxapine—Asthenia—Doxorubicin—lung cancer	0.000199	0.0004	CcSEcCtD
Loxapine—Pruritus—Doxorubicin—lung cancer	0.000196	0.000395	CcSEcCtD
Loxapine—Diazepam—ABCB1—lung cancer	0.000191	0.0254	CrCbGaD
Loxapine—Nausea—Methotrexate—lung cancer	0.00019	0.000383	CcSEcCtD
Loxapine—Clozapine—ABCB1—lung cancer	0.000188	0.0251	CrCbGaD
Loxapine—Dizziness—Doxorubicin—lung cancer	0.000183	0.000369	CcSEcCtD
Loxapine—Vomiting—Doxorubicin—lung cancer	0.000176	0.000355	CcSEcCtD
Loxapine—Rash—Doxorubicin—lung cancer	0.000174	0.000352	CcSEcCtD
Loxapine—Dermatitis—Doxorubicin—lung cancer	0.000174	0.000352	CcSEcCtD
Loxapine—Headache—Doxorubicin—lung cancer	0.000173	0.00035	CcSEcCtD
Loxapine—Nausea—Doxorubicin—lung cancer	0.000164	0.000332	CcSEcCtD
Loxapine—CHRM2—Signaling Pathways—CCND1—lung cancer	8.17e-06	2.1e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—PTEN—lung cancer	8.16e-06	2.09e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—JUN—lung cancer	8.15e-06	2.09e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—CCND1—lung cancer	8.15e-06	2.09e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—HRAS—lung cancer	8.13e-06	2.09e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—JUN—lung cancer	8.13e-06	2.09e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CXCL8—lung cancer	8.12e-06	2.08e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—VEGFA—lung cancer	8.12e-06	2.08e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—TP53—lung cancer	8.08e-06	2.07e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—MMP9—lung cancer	8.08e-06	2.07e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—MYC—lung cancer	8.08e-06	2.07e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—HRAS—lung cancer	8.07e-06	2.07e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—MMP9—lung cancer	8.06e-06	2.07e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—CDKN1A—lung cancer	8.05e-06	2.06e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—STAT3—lung cancer	8.04e-06	2.06e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—MMP9—lung cancer	8.03e-06	2.06e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—CDKN1A—lung cancer	8.03e-06	2.06e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—PTEN—lung cancer	8.03e-06	2.06e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—NRAS—lung cancer	8.02e-06	2.06e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—PTEN—lung cancer	8.01e-06	2.06e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—MMP9—lung cancer	8.01e-06	2.05e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—CDKN1A—lung cancer	8.01e-06	2.05e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—PIK3CA—lung cancer	8e-06	2.05e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—MYC—lung cancer	8e-06	2.05e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—VEGFA—lung cancer	8e-06	2.05e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—PTEN—lung cancer	7.99e-06	2.05e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—CDKN1A—lung cancer	7.98e-06	2.05e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—HRAS—lung cancer	7.96e-06	2.04e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling by GPCR—AKT1—lung cancer	7.96e-06	2.04e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—PTEN—lung cancer	7.96e-06	2.04e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—MAPK3—lung cancer	7.94e-06	2.04e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—MMP9—lung cancer	7.93e-06	2.03e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—STAT3—lung cancer	7.92e-06	2.03e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—MMP9—lung cancer	7.91e-06	2.03e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—CDKN1A—lung cancer	7.9e-06	2.03e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—MAPK3—lung cancer	7.9e-06	2.03e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—EGFR—lung cancer	7.9e-06	2.03e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—NRAS—lung cancer	7.9e-06	2.03e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—PTEN—lung cancer	7.88e-06	2.02e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—CDKN1A—lung cancer	7.88e-06	2.02e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—PTEN—lung cancer	7.86e-06	2.02e-05	CbGpPWpGaD
Loxapine—ADRA2A—GPCR downstream signaling—AKT1—lung cancer	7.85e-06	2.01e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—IL6—lung cancer	7.84e-06	2.01e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—HRAS—lung cancer	7.84e-06	2.01e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—IL6—lung cancer	7.84e-06	2.01e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling by GPCR—AKT1—lung cancer	7.83e-06	2.01e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—EGFR—lung cancer	7.83e-06	2.01e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling by GPCR—AKT1—lung cancer	7.82e-06	2.01e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling by GPCR—AKT1—lung cancer	7.79e-06	2e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—IL6—lung cancer	7.78e-06	2e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—EP300—lung cancer	7.78e-06	2e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CASP3—lung cancer	7.78e-06	1.99e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling by GPCR—AKT1—lung cancer	7.77e-06	1.99e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—IL2—lung cancer	7.76e-06	1.99e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—TP53—lung cancer	7.74e-06	1.99e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—HRAS—lung cancer	7.73e-06	1.98e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—IL6—lung cancer	7.73e-06	1.98e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—MYC—lung cancer	7.72e-06	1.98e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling by GPCR—AKT1—lung cancer	7.69e-06	1.97e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—MAPK3—lung cancer	7.69e-06	1.97e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—MYC—lung cancer	7.68e-06	1.97e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling by GPCR—AKT1—lung cancer	7.67e-06	1.97e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—EP300—lung cancer	7.66e-06	1.96e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—EP300—lung cancer	7.64e-06	1.96e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—PIK3CA—lung cancer	7.63e-06	1.96e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—IL6—lung cancer	7.62e-06	1.96e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—EP300—lung cancer	7.62e-06	1.95e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—EP300—lung cancer	7.59e-06	1.95e-05	CbGpPWpGaD
Loxapine—ADRA2C—Metabolism—PIK3CA—lung cancer	7.59e-06	1.95e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CCND1—lung cancer	7.57e-06	1.94e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—SRC—lung cancer	7.57e-06	1.94e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—MAPK3—lung cancer	7.56e-06	1.94e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—EGFR—lung cancer	7.56e-06	1.94e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—JUN—lung cancer	7.55e-06	1.94e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—PIK3CA—lung cancer	7.52e-06	1.93e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—EP300—lung cancer	7.52e-06	1.93e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—EGFR—lung cancer	7.52e-06	1.93e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—IL6—lung cancer	7.5e-06	1.92e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—EP300—lung cancer	7.5e-06	1.92e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—MYC—lung cancer	7.47e-06	1.92e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—KRAS—lung cancer	7.46e-06	1.91e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—SRC—lung cancer	7.45e-06	1.91e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—SRC—lung cancer	7.43e-06	1.91e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—SRC—lung cancer	7.41e-06	1.9e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—HRAS—lung cancer	7.4e-06	1.9e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—IL6—lung cancer	7.4e-06	1.9e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—KRAS—lung cancer	7.39e-06	1.9e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—SRC—lung cancer	7.38e-06	1.89e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—TP53—lung cancer	7.38e-06	1.89e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—VEGFA—lung cancer	7.37e-06	1.89e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—MYC—lung cancer	7.36e-06	1.89e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—MMP9—lung cancer	7.35e-06	1.89e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CDKN1A—lung cancer	7.32e-06	1.88e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—SRC—lung cancer	7.31e-06	1.88e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—EGFR—lung cancer	7.31e-06	1.88e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—PTEN—lung cancer	7.31e-06	1.87e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—STAT3—lung cancer	7.3e-06	1.87e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—SRC—lung cancer	7.29e-06	1.87e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—NRAS—lung cancer	7.28e-06	1.87e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—TP53—lung cancer	7.28e-06	1.87e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—VEGFA—lung cancer	7.25e-06	1.86e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—VEGFA—lung cancer	7.24e-06	1.86e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—AKT1—lung cancer	7.24e-06	1.86e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—AKT1—lung cancer	7.23e-06	1.85e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—VEGFA—lung cancer	7.21e-06	1.85e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—EGFR—lung cancer	7.2e-06	1.85e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—VEGFA—lung cancer	7.19e-06	1.84e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—AKT1—lung cancer	7.18e-06	1.84e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—STAT3—lung cancer	7.18e-06	1.84e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—STAT3—lung cancer	7.17e-06	1.84e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—NRAS—lung cancer	7.16e-06	1.84e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—NRAS—lung cancer	7.15e-06	1.83e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—STAT3—lung cancer	7.14e-06	1.83e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—KRAS—lung cancer	7.14e-06	1.83e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—AKT1—lung cancer	7.13e-06	1.83e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—NRAS—lung cancer	7.13e-06	1.83e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—VEGFA—lung cancer	7.12e-06	1.83e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—STAT3—lung cancer	7.12e-06	1.83e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—NRAS—lung cancer	7.1e-06	1.82e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—VEGFA—lung cancer	7.1e-06	1.82e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—KRAS—lung cancer	7.1e-06	1.82e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—IL6—lung cancer	7.09e-06	1.82e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—HRAS—lung cancer	7.06e-06	1.81e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—STAT3—lung cancer	7.05e-06	1.81e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—NRAS—lung cancer	7.03e-06	1.8e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—AKT1—lung cancer	7.03e-06	1.8e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—STAT3—lung cancer	7.03e-06	1.8e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—NRAS—lung cancer	7.02e-06	1.8e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—MAPK3—lung cancer	6.97e-06	1.79e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—EP300—lung cancer	6.97e-06	1.79e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—HRAS—lung cancer	6.96e-06	1.79e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—AKT1—lung cancer	6.92e-06	1.78e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—KRAS—lung cancer	6.91e-06	1.77e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—MAPK3—lung cancer	6.86e-06	1.76e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—PIK3CA—lung cancer	6.86e-06	1.76e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—MAPK3—lung cancer	6.85e-06	1.76e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—AKT1—lung cancer	6.83e-06	1.75e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—MAPK3—lung cancer	6.82e-06	1.75e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—MAPK3—lung cancer	6.8e-06	1.75e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—KRAS—lung cancer	6.8e-06	1.74e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—PIK3CA—lung cancer	6.79e-06	1.74e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—MYC—lung cancer	6.78e-06	1.74e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—SRC—lung cancer	6.78e-06	1.74e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—IL6—lung cancer	6.75e-06	1.73e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—MAPK3—lung cancer	6.74e-06	1.73e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—MAPK3—lung cancer	6.72e-06	1.72e-05	CbGpPWpGaD
Loxapine—CHRM3—Metabolism—PIK3CA—lung cancer	6.72e-06	1.72e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—MYC—lung cancer	6.67e-06	1.71e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—IL6—lung cancer	6.66e-06	1.71e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—MYC—lung cancer	6.66e-06	1.71e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—MYC—lung cancer	6.64e-06	1.7e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—EGFR—lung cancer	6.63e-06	1.7e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—TP53—lung cancer	6.63e-06	1.7e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—MYC—lung cancer	6.62e-06	1.7e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—VEGFA—lung cancer	6.6e-06	1.69e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—TP53—lung cancer	6.57e-06	1.69e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—PIK3CA—lung cancer	6.56e-06	1.68e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—MYC—lung cancer	6.55e-06	1.68e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—AKT1—lung cancer	6.54e-06	1.68e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—MYC—lung cancer	6.53e-06	1.68e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—STAT3—lung cancer	6.53e-06	1.68e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—EGFR—lung cancer	6.53e-06	1.67e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—PIK3CA—lung cancer	6.52e-06	1.67e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—NRAS—lung cancer	6.52e-06	1.67e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—EGFR—lung cancer	6.51e-06	1.67e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—EGFR—lung cancer	6.49e-06	1.67e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—EGFR—lung cancer	6.47e-06	1.66e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—EGFR—lung cancer	6.41e-06	1.64e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—EGFR—lung cancer	6.39e-06	1.64e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—PIK3CA—lung cancer	6.35e-06	1.63e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—TP53—lung cancer	6.34e-06	1.63e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—HRAS—lung cancer	6.34e-06	1.63e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—TP53—lung cancer	6.31e-06	1.62e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—HRAS—lung cancer	6.28e-06	1.61e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—KRAS—lung cancer	6.27e-06	1.61e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—PIK3CA—lung cancer	6.24e-06	1.6e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—MAPK3—lung cancer	6.24e-06	1.6e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—AKT1—lung cancer	6.23e-06	1.6e-05	CbGpPWpGaD
Loxapine—ADRA2C—Metabolism—AKT1—lung cancer	6.2e-06	1.59e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—KRAS—lung cancer	6.17e-06	1.58e-05	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—PIK3CA—lung cancer	6.16e-06	1.58e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—KRAS—lung cancer	6.15e-06	1.58e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—AKT1—lung cancer	6.15e-06	1.58e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—TP53—lung cancer	6.14e-06	1.57e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—KRAS—lung cancer	6.13e-06	1.57e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—KRAS—lung cancer	6.11e-06	1.57e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—MYC—lung cancer	6.07e-06	1.56e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—IL6—lung cancer	6.07e-06	1.56e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—HRAS—lung cancer	6.07e-06	1.56e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—KRAS—lung cancer	6.05e-06	1.55e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—TP53—lung cancer	6.04e-06	1.55e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—KRAS—lung cancer	6.04e-06	1.55e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—HRAS—lung cancer	6.04e-06	1.55e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—IL6—lung cancer	6.02e-06	1.54e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—EGFR—lung cancer	5.94e-06	1.52e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—HRAS—lung cancer	5.87e-06	1.51e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—IL6—lung cancer	5.81e-06	1.49e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—HRAS—lung cancer	5.78e-06	1.48e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—IL6—lung cancer	5.78e-06	1.48e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—PIK3CA—lung cancer	5.76e-06	1.48e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—PIK3CA—lung cancer	5.67e-06	1.45e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—PIK3CA—lung cancer	5.65e-06	1.45e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—PIK3CA—lung cancer	5.63e-06	1.45e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—IL6—lung cancer	5.62e-06	1.44e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—PIK3CA—lung cancer	5.62e-06	1.44e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—KRAS—lung cancer	5.61e-06	1.44e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—AKT1—lung cancer	5.6e-06	1.44e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—TP53—lung cancer	5.57e-06	1.43e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—PIK3CA—lung cancer	5.56e-06	1.43e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—AKT1—lung cancer	5.55e-06	1.42e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—PIK3CA—lung cancer	5.55e-06	1.42e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—IL6—lung cancer	5.53e-06	1.42e-05	CbGpPWpGaD
Loxapine—CHRM3—Metabolism—AKT1—lung cancer	5.49e-06	1.41e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—TP53—lung cancer	5.48e-06	1.41e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—TP53—lung cancer	5.47e-06	1.4e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—TP53—lung cancer	5.45e-06	1.4e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—TP53—lung cancer	5.43e-06	1.39e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—TP53—lung cancer	5.38e-06	1.38e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—TP53—lung cancer	5.37e-06	1.38e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—AKT1—lung cancer	5.36e-06	1.37e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—AKT1—lung cancer	5.33e-06	1.37e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—HRAS—lung cancer	5.33e-06	1.37e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—HRAS—lung cancer	5.24e-06	1.34e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—HRAS—lung cancer	5.23e-06	1.34e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—HRAS—lung cancer	5.21e-06	1.34e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—HRAS—lung cancer	5.2e-06	1.33e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—AKT1—lung cancer	5.18e-06	1.33e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—PIK3CA—lung cancer	5.15e-06	1.32e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—HRAS—lung cancer	5.15e-06	1.32e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—HRAS—lung cancer	5.13e-06	1.32e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—AKT1—lung cancer	5.1e-06	1.31e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—IL6—lung cancer	5.1e-06	1.31e-05	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—AKT1—lung cancer	5.04e-06	1.29e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—IL6—lung cancer	5.02e-06	1.29e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—IL6—lung cancer	5.01e-06	1.28e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—IL6—lung cancer	4.99e-06	1.28e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—TP53—lung cancer	4.99e-06	1.28e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—IL6—lung cancer	4.97e-06	1.28e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—IL6—lung cancer	4.93e-06	1.26e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—IL6—lung cancer	4.91e-06	1.26e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—HRAS—lung cancer	4.77e-06	1.22e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—AKT1—lung cancer	4.7e-06	1.21e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—AKT1—lung cancer	4.63e-06	1.19e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—AKT1—lung cancer	4.62e-06	1.18e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—AKT1—lung cancer	4.6e-06	1.18e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—AKT1—lung cancer	4.59e-06	1.18e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—IL6—lung cancer	4.56e-06	1.17e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—AKT1—lung cancer	4.54e-06	1.17e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—AKT1—lung cancer	4.53e-06	1.16e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—AKT1—lung cancer	4.21e-06	1.08e-05	CbGpPWpGaD
